# Boehringer Ingelheim的survodutide在晚期試驗中平均減重高達16.6%。

*biotech · news · 2026-04-28 · Devdiscourse*

## Key points

- Boehringer Ingelheim的survodutide在第三期肥胖症試驗中達成16.6%的平均體重減輕。
- SYNCHRONIZE-1試驗涉及無第二型糖尿病的肥胖或超重成人。
- Survodutide模擬GLP-1和胰高血糖素兩種激素，可能增強減重效果。
- 完整的第三期試驗結果將於2026年美國糖尿病協會科學會議上公布。

​Boehringer Ingelheim said on Tuesday ‌its experimental ​obesity drug led to average weight loss of up to 16.6% in a late-stage ‌trial, as the unlisted German drugmaker seeks to catch up with obesity drug pioneers Eli Lilly and Novo Nordisk. The Phase III trial showed patients ‌treated with survodutide lost 16.6% of their body weight after 76 ‌weeks, compared with 3.2% in a placebo group, Boehringer said in a statement. Participants were obese or overweight adults without type 2 diabetes. Boehringer acquired the rights in ⁠2011 to ​solely develop ⁠and commercialise survodutide from Denmark's Zealand Pharma, which is entitled to royalty payments on global ⁠revenue. Full results from the Phase III study, called SYNCHRONIZE-1, will be presented ​at the American Diabetes Association's 2026 Scientific Sessions, scheduled from June ⁠5 to June 8. Survodutide mimics the appetite-suppressing gut hormone GLP-1, targeted by injectable drugs ⁠such ​as Novo's Wegovy, but also imitates the gut hormone glucagon, a combination some developers hope will boost weight loss. Altimmune is developing ⁠a drug based on the effects of the same two hormones. In early ⁠2024, survodutide ⁠delivered promising mid-stage results in the treatment of fatty liver, also known as metabolic dysfunction-associated steatohepatitis, or MASH. (This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

**Companies:** Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Zealand Pharma, Altimmune
**Countries:** Germany, Denmark

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3889014-refile-boehringer-zealand-drug-leads-to-166-weight-loss-in-late-stage-trial)

---

Canonical: https://newsio.io/zh-TW/n/3b1afa6a-2ff5-47a1-b450-666acb0b0900/boehringer-ingelheimsurvodutide16-6eli-lillynovo-nordisk
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works